PCR

News on qPCR, digital PCR, amplification, point-of-care testing platforms in genetics, genomics, and molecular diagnostics.

The RightMed test covers 22 genes in which variants are known to contribute to the effectiveness or safety of more than 340 drugs for more than 20 indications.

Ascendas will develop and commercialize molecular diagnostic systems and assays using certain of Fluidigm's microfluidic technologies.

Qiagen's revenues grew 6 percent at constant exchange rates to $349.0 million, besting the average Wall Street estimate of $346.6 million.

Based in Beverly, Massachusetts, the biotechnology company aims to have the pathogen detection technology on the market by the end of 2018.

The firm's life science segment grew revenues 8 percent, but revenues from its diagnostics segment saw revenues retreated 4 percent.